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Abstract
Background: There are very few studies on reasons for loss to follow-up from TB treatment in Central Asia. This
study assessed risk factors for LTFU and compared their occurrence with successfully treated (ST) patients in Tajikistan.
Methods: This study took place in all TB facilities in the 19 districts with at least 5 TB patients registered as loss to
follow-up (LTFU) from treatment. With a matched case control design we included all LTFU patients registered in the
selected districts in 2011 and 2012 as cases, with ST patients from the same districts being controls. Data were copied
from patient records and registers. Conditional logistic regressions were run to analyse associations between collected
variables and LTFU as dependent variable.
Results: Three hundred cases were compared to 592 controls. Half of the cases had migrated or moved. In
multivariate analysis, risk factors associated with increased LTFU were migration to another country (OR 10.6,
95% CI 6.12–18.4), moving within country (OR 11.0, 95% CI 3.50–34.9), having side effects of treatment (OR 3.
67, 95% CI 1.68–8.00) and being previously treated for TB (OR 2.03, 95% CI 1.05–3.93). Medical staff also mentioned
patient refusal, stigma and family problems as risk factors.
Conclusions: LTFU of TB patients in Tajikistan is largely a result of migration, and to a lesser extent associated with
side-effects and previous treatment. There is a need to strengthen referral between health facilities within Tajikistan and
with neighbouring countries and support patients with side effects and/or previous TB to prevent loss to follow-up from
treatment.
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Background
TB patients lost to follow-up (LTFU) are defined as “TB
patients who did not start treatment or whose treatment
was interrupted for two consecutive months or more”
[1] and were previously called defaulters. LTFU patients
are more likely to redevelop infectious active TB, and
are at higher risk of developing MDR-TB [2].
Reasons and risk factors for LTFU have been described
extensively, but rarely in countries of the Central Asia
Region (CAR) [3–8]. Only two such studies have been
reported from Uzbekistan, a quantitative and qualitative
one in Tashkent [9, 10]. The quantitative study found
that unemployment, being a pensioner, alcoholism and
homelessness were associated with default [10]. Few
studies on this subject were reported from other former
Soviet Union countries, for example from Latvia, [11]
Russia [12, 13], Moldova [14], Estonia [15], Armenia
[16] and Georgia [17]. They found a large variety of
socio-economic and clinical risk factors to be associated
with LTFU.
In Tajikistan, no such study has been reported.
Although Tajikistan reported a low proportion LTFU
among new and retreatment cases in the last few years
(4%) [18], this is considered to be an underestimate.
Tajikistan reported 77% multidrug-resistant (MDR) TB
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among previously treated TB cases and 14% MDR TB
among newly diagnosed cases in the cohort 2014
[19].This is probably partly a result of incomplete treat-
ment in the past. Therefore it is important to under-
stand the drivers and results of LTFU in Tajikistan to
achieve successful treatment outcomes.
This study aimed at determining risk factors for TB
patients LTFU and comparing them with patients suc-
cessfully treated. We also studied factors that have rarely
been reported, for example outmigration rather than in-
migration, which is a special problem in CAR due to the
attraction of labour opportunities in Russia.
Methods
Setting
Tajikistan notified to WHO 7035 TB cases in 2011 and
6508 in 2012, of whom 604 and 694 were confirmed
MDR cases. The WHO estimated incidence rate in
Tajikistan was 87 per 100,000 in 2016. In 2016 a total of
6232 TB patients were registered for treatment in
Tajikistan [19].
Design
We chose a matched case-control design for efficiency,
since the proportion of patients LTFU is reported to be
only 4%. Patients registered for treatment who became
LTFU (as defined by WHO [1]) were defined as cases.
Patients diagnosed with TB who did not start treatment
are also part of the official WHO definition, but could
not be included since they were not registered as such.
For each case, two successfully treated (ST) patients fol-
lowing them in the same register were chosen as con-
trols, in effect matching them only on health facility and
time of registration (controls had date of registration
near that of a case) rather than on the basis of individual
characteristics. If any of them was not ST, the next ST
patient on the list was chosen as a control.
Study population
The study population consisted only of TB patients reg-
istered for first line treatment in 2011 and 2012, who
were marked as defaulters (now called LTFU) or suc-
cessfully treated in the TB registers. In Tajikistan pa-
tients who migrated or moved are defined as LTFU,
except when further treatment in a different location is
confirmed. Therefore migrated and moved patients
marked as LTFU were included as cases in the study. It
should be noted that patients who move AND report in
another clinic for continuation of treatment, were regis-
tered as ‘transfer out’ and have been excluded from this
study. About 1% of patients had a treatment outcome
registered as ‘transfer out’ in 2011.
Sampling method and size
Multistage purposeful sampling was used to maximize
the number of LTFU patients found visiting a minimum
number of facilities. Patients were selected from TB
registers located in regional TB centres. Tajikistan has 5
administrative areas: Sughd, Khatlon, region under repub-
lican sub-ordination, Dushanbe and Gorno-Badakhshan
Autonomous region (GBAO), with together 59 districts.
We selected all districts that each had at least five LTFU
DS-TB patients registered for treatment in 2011 [18].
These were 19 districts within 4 administrative areas (only
1 patient LTFU was registered in GBAO in 2011 and this
whole region was excluded).
Data collection and validation
Data collection took place in all 34 TB centres between
May and June 2014 in the 19 selected districts. Informa-
tion was taken from TB registers and individual patient
records, while facility medical staff were consulted when
additional information was needed or when information
in registers contradicted patient records.1 The risk fac-
tors measured in the study were those registered in the
patient records. Factors such as homelessness and alco-
holism had no systematic definition in the patient re-
cords, and were based on the observations made by TB
clinicians.
An electronic data collection form was developed
using the Russian translation of EpiData [20] to obtain
information from the TB registers TB03/TB0 3 U, TB01/
TB0 1 U. [http://www.who.int/tb/dots/r_and_r_forms/
en/], patient records and laboratory registers from TB
centres. The tool enabled the direct entry of data ex-
tracted from paper documents in an electronic database.
To ensure quality, the data entry form was tested in a
pilot by two of the researchers, who also participated
during the actual data collection to enter data.
Data have been collected by trained study clinicians
and epidemiologists in 4 teams of 2 persons each.
During the course of data collection the teams held con-
tact via phone in order to solve problems concerning the
use of different codes and other queries, ensuring
consistency between the teams.
We also asked medical staff (the treating clinician and
nurse, whoever knew most about the patient) what was
the reason for LTFU according to the health care pro-
vider, for each individual patient LTFU.
Data analysis
For data cleaning and analysis the database was exported
from EpiData into SPSS 21 for Windows (SPSS, Inc.,
Chicago, USA). First univariate conditional logistic re-
gressions were run to analyse associations between col-
lected variables and LTFU as dependent variable. Since
each case had more than one control the Cox regression
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command was used to perform conditional logistic re-
gression. Variables with significant associations in the
univariate models were included in a multivariate condi-
tional logistic regression model using the likelihood ratio
with backward selection of independent variables. 95%
confidence intervals (CI) were calculated for all variables
included in the univariate and multivariate regressions.
Permission and informed consent
Official permission to conduct this study was issued by
the National Ethics Committee of the Ministry of Health
(MoH) Tajikistan, and all facility directors gave permis-
sion to participate prior to data collection. Data from TB
registers, patient medical records and laboratory regis-
ters could only be matched by patient names, which
were deleted immediately after linking was completed.
Results
Selection and characteristics of study population
According to the national TB database, 503 patients
were LTFU in Tajikistan among the cohorts diagnosed
and on first line treatment in 2011 and 2012 [20]
(Table 1). This is 4% of the cases notified to WHO
whom did not have confirmed MDR (6431 and 5814,
respectively). Among them 334 TB patients (64%)
were registered in the 19 districts. Two controls were
selected per case, therefore 644 ST patients were expected.
Only 300 (89.8%) of the expected 334 LTFU patients were
actually found in the registers. The others had successful
or unclear treatment outcomes or errors in registers such
as a missing final sputum test which was not actually
missing but just not entered in the register. Only
83.9% of reported LTFU patients could be retrieved
from the registers in 2011 and 95.4% in 2012. The
300 LTFU cases have been matched with 644 successfully
treated patients (controls) of whom 592 had complete
enough data to include them (91.9%).
The majority of ST and LTFU patients in the study
population were male (n = 316; 53.4%, n = 202; 67.3%
respectively), between 19 and 40 years of age (n = 316;
53.4%, n = 202; 67.3%), living in rural areas (n = 455;
76.9%, n = 236; 78.7%), had PTB (n = 434; 73.3%,
n = 253; 84.3%), of which slightly less than half were
confirmed smear-positive at baseline (n = 229; 38.7%,
n = 140; 46.7%) (Table 2). Only 9.2% of all TB patients
registered in 2011 were tested for drug resistance at time
of diagnosis.
The majority (69%) of ST patients were smear-
negative at end of treatment, the others had unknown
smear status. Among those LTFU, the proportion of
those who were lost to follow up from TB treatment
during the intensive treatment phase (34%) was lower
than during the continuation phase (59%), the remainder
was unknown.
Factors associated with loss to follow-up
Univariate analysis
The univariate analysis showed that being male (OR = 1.78;
95% CI 1.33–2.40), having side effects (OR = 3.22;
CI = 1.64–6.33), being previously treated for TB
(OR = 2.86; CI = 1.70–4.82), patient category other
(OR = 1.96; CI = 1.27–3.02), having moved within country
(OR = 10.7; CI = 4.08–28.1) or migrating out of the coun-
try (OR = 9.70; CI = 6.06–15.5), homelessness (OR 2.63,
CI = 1.19–5.82) and ever abusing drugs (OR = 5.21;
CI = 1.02–26.6) were significantly positively associated
with LTFU from treatment (Table 2). The strongest risk
factor was moving within or out of country, both as com-
pared to not moving. Forty percent of patients LTFU mi-
grated out of country and 9% within country.
All age groups had a significantly lower risk of LTFU
when compared to the largest age group of 19–40 years
(Table 2). Other groups who have a lower risk of LTFU
were those whose baseline smear was not performed
(OR = 0.57; CI = 0.37–0.86), those having EPTB
(OR = 0.49; CI = 0.34–0.72), those still being in school
(OR = 0.45; CI = 0.23–0.89) and pensioners (OR = 0.51;
CI = 0.27–0.93).
Other factors not significantly associated with
LTFU were rural/urban place of living, seasonal
work, alcohol abuse, employment, pregnancy, home-
lessness and hospitalization during intensive treat-
ment phase (Table 2).
For type of drug-resistance an HIV there were too few
patients with test results to do a meaningful analysis.
Multivariate analysis
The factors sex, age group, TB location, side effects,
patient category, migration out of Tajikistan, and
moved within country were included in the stepwise
model for the multivariate analysis. Out of these
factors, only having side effects (OR = 3.67; CI = 1.68–
8.00), being previously treated (OR = 2.3; CI = 1.05–3.93),
moved within country (OR = 11.04; CI = 3.50–34.9)
Table 1 Selection of patients and those actually found
Cases (LTFU) 2 controls (ST)
per case
2011 2012 Total Total
Registered in
national database
DS TB DS TB
Country 241 262 503
19 Selected Districts
with > = 5 patients
LTFU
161
(66.8%)
173
(66.0%)
334
(66.4%)
644
Found in registers 135
(83.9%)
165
(95.4%)
300
(89.8%)
592
(91.9%)
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Table 2 Univariate analyses of factors associated with loss to follow-up
Factors Loss to follow-up Successful Treated Crude Odds Ratio CI (95%)
N Column % N Column %
Totals 300 592
Sex
Males 202 67.3 316 53.4 1.78 1.33–2.40
Females 98 32.7 276 46.6 ref
Age group
0–18 19 6.3 83 14.0 0.36 0.21–0.62
19–40 202 67.3 316 53.4 ref
41–60 57 19.0 136 23.0 0.68 0.47–0.97
>60 21 7.0 57 9.6 0.55 0.32–0.95
Unknown 1 0.3
Place of Living
Rural 236 78.7 455 76.9 ref
Urban 56 18.7 132 22.3 0.59 0.29–1.20
Unknown 8 2.7 5 0.8
Baseline smear result
Baseline smear negative 112 37.2 212 35.8 ref
Baseline smear positive 140 46.7 229 38.7 1.15 0.83–1.59
Baseline smear not done 48 16.1 150 25.3 0.57 0.37–0.86
Unknown 1 0.2
Location of TB
PTB 253 84.3 434 73.3 ref
EPTB 47 15.7 158 26.7 0.49 0.34–0.72
Patient category
New 211 70.3 495 83.6 Ref
Previously treated 40 13.3 34 5.7 2.86 1.70–4.82
Transferred in 2 0.7 4 0.7 1.39 0.20–9.48
Other 47 15.7 58 9.8 1.96 1.27–3.02
Unknown 1 0.2
Pregnancy
Pregnancy no 75 25.0 202 34.1 ref
Pregnancy yes 3 1.0 2 0.3 65.3 0 - >100
Pregnancy na. 217 72.3 371 62.7
Unknown 5 1.7 17 2.5
Side effects
Side effects no 237 79.0 520 87.8 ref
Side effects yes 26 8.7 19 3.2 3.22 1.64–6.33
Unknown 37 12.3 53 9.0
Moved within country
Moved no 264 88.0 570 96.3 ref
Moved yes 26 8.7 7 1.2 10.7 4.08–28.1
Unknown 10 3.3 15 2.5
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Table 2 Univariate analyses of factors associated with loss to follow-up (Continued)
Seasonal work
Seasonal work no 283 94.3 568 95.9 ref
Seasonal work yes 6 2.0 11 1.9 1.02 0.36–2.90
Unknown 11 3,7 13 2.1
Migration other country
Migration no 167 55.7 534 90.2 ref
Migration yes 123 41.0 44 7.4 9.70 6.06–15.5
Unknown 10 3.3 14 2.4
Imprisonment ever
Imprisonment no/unknown 292 96.8 585 98.8 ref
Imprisonment yes 8 3.2 7 1.2 2.19 0.74–6.46
Alcoholism
Alcoholism no 247 82.3 540 91.2 ref
Alcoholism yes 13 4.4 14 2.4 1.87 0.82–4.28
Unknown 40 13.3 38 6.4
Drug abuse
Drug abuse no 253 84.3 551 93.1 ref
Drug abuse yes 6 2.0 3 0.5 5.21 1.02–26.6
Unknown 41 13.7 38 6.4
Employment
Unemployed 237 79.0 364 61.5 ref
Working 17 5.7 39 6.6 0.68 0.36–1.27
Student 6 2 23 3.9 0.40 0.16–1.05
Pensioner 18 6.0 55 9.3 0.51 0.27–0.93
Not applicable 17 5.7 73 12.3
Unknown 5 1.7 38 6.4
Education
Middle school 249 83.0 432 73.0 ref
College 4 1.3 19 3.2 0.51 0.16–1.58
University 8 2.7 16 2.7 0.84 0.35–2.04
Still studying 11 3.7 45 7.6 0.45 0.23–0.89
No degree 11 3.7 30 5.1 0.57 0.26–1.24
Unknown 17 5.6 50 8.4
Homelessness
Homelessness no 281 93.7 575 97.1 ref
Homelessness yes 15 5.0 15 2.5 2.63 1.19–5.82
Unknown 4 1.3 2 0.3
Hospitalization
ambulatory 146 48.7 292 49.3 ref
hospital 152 50.7 296 50.0 1.07 0.78–1.47
Different country 1 0.3 3 0.5 0.75 0.08–7.23
Prison hospital 1 0.3 1 0.2 2.58 0.16–42.3
Ref = reference category
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and migration to another country (OR = 10.6;
CI = 6.12–18.4) had a significant association with
LTFU (Table 3). As in the univariate analyses the as-
sociation was strongest for the factors moved within
country and migration to another country, and with
slightly higher odds ratios.
Medical staff mentioned a reason for LTFU for
292 out of 317 (92%) patients LTFU. They con-
firmed that the majority of TB patients was lost to
follow-up due to migration to another country (50%
of 292) or within Tajikistan (10%), with other rea-
sons mentioned often refusing further treatment
(15%), and side effects (8%), stigma (5%) and family
problems (5%).
Discussion
We found that the main factors associated with LTFU
were migration out of country, moving within country,
side effects and previous treatment. Medical staff con-
firmed these but also mentioned patients refusing fur-
ther treatment, stigma and family problems.
Treatment phase during LTFU
LTFU occurred more often in the continution phase
(58.8%) than in the intensive phase of treatment (34.2%).
Conversely, an older study (2007) on default in
Uzbekistan found that the majority of LTFU cases inter-
rupted treatment in the intensive phase (62%) [10]. At
the time of our study, Tajikistan was more advanced in
decentralizing services to primary health care facilities
than was Uzbekistan; therefore, patients in Tajikistan
may have stayed on treatment longer.
Risk factors
We found the main risk factor for LTFU in Tajikistan
was migration to another country. To our knowledge,
this has not been reported before, except in Moldova,
where spending more than three months abroad within
the past year was a risk factor for LTFU. For example a
similar study in Uzbekistan did not find this [10]. Many
Tajiks migrate to Russia for work. Often when during
migration they are diagnosed with TB, they are sent
home for treatment. TB treatment in Tajikistan means a
substantial drop in financial support for families due to
lost wages. Although TB treatment and diagnosis should
be free of charge, certain diagnostic procedures and add-
itional medication accompanying TB treatment often
have to be paid out of pocket. This is a major burden for
patients and their families and increases the motivation
to leave the country for work again even if patients have
not successfully completed treatment [21].
In contrast to the situation in Central Asia, studies glo-
bally found a relationship between being an immigrant
coming from another country and LTFU [13, 23–28].
Most of those studies were conducted in European Union
(EU) member states or USA where over a third of the re-
ported TB cases are immigrants. In combination with our
study, this shows that migration - regardless whether out
of or into a country or within a country- may inhibit com-
pletion of TB treatment.
For the variable patient category, being previously
treated showed a significant positive association with
LTFU, as was found elsewhere [14, 15, 17, 26]. This
means that patients who already received TB treatment
were more likely to be LTFU from subsequent treat-
ments, including patients with a relapse, former treat-
ment failure, after LTFU, and transferred patients.
Our finding that side effects were associated with loss
to follow-up, was also found by others [15]. Most studies
do not report on an association between LTFU and side
effects, possibly since side-effects are often not recorded
in a standard way in TB records [4]. An association with
LTFU is expected for individuals taking MDR-TB drugs
since second line drugs are more toxic and more likely
to cause severe side effects.
Many studies have found other factors significantly as-
sociated with LTFU, such as alcohol use and drug addic-
tion [12, 14, 16, 22, 29–31]. We could not confirm these,
possibly since the factor migration was so strong in our
study population. Another reason may be that these fac-
tors may not have been noted accurately since alcohol
and drug abuse are not socially acceptable in the local
culture. Even though every patient diagnosed with TB is
tested for HIV as of 2010, many physicians do not note
this in the TB registers [32].
Another risk factor that was found to be significant in
many other studies but not significant at all in ours was
Table 3 Factors associated with loss to follow-up in multivariate
analysis
Factor Na Adjusted Odds Ratio CI (95%)
Side effects
Side effects no 769 ref
Side Effects yes 69 3.67 1.68–8.00
Patient category
New case 646 ref
Retreatment case 96 2.03 1.05–3.93
Other 94 1.65 0.89–3.06
Moved within country
Moved no 808 ref
Moved yes 28 11.04 3.50–34.9
Migration other country
Migration no 676 Ref
Migration yes 160 10.6 6.12–18.4
an = 836, due to exclusion of those with missing values
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hospitalization versus ambulatory treatment [10, 30, 33].
Hospitalization during intensive phase is common prac-
tice in Tajikistan. Possibly the result of the analysis is re-
lated to a clear pre-selection of patients to be
hospitalized in Tajikistan since 2011–2012. Alternatively,
we may not have measured the actual risk factor, which
is: being released from hospitalization to ambulatory
care without proper follow-up [10, 30].
Reasons for LTFU given by medical staff
The factors mentioned by the clinical staff, such as
stigma, family problems and patient refusing to take
more treatment, were within FSU countries also found
in Uzbekistan and Armenia [9, 10, 15]. We also
attempted in-depth interviews in a later cohort that was
LTFU and could interview only 20 of the patients loss to
follow-up. Half of those patients still had TB and 6/20
thought they had completed treatment. Although these
numbers low, they indicate that there may be communi-
cation issues between medical staff and patients on
treatment completion.
Strength and limitations
The strength of this study was that it was the first in its
kind reported from Tajikistan, and the only recent one
from the central Asian region, included a large number
of patients and is largely generalizable to the country. A
limitation was that only variables available in medical re-
cords could be analyzed. Further drug sensitivity testing
was not standard yet at time of the study. Lastly, it is
possible that answers from medical staff on reasons for
LTFU were influenced by recall bias.
Conclusions
In conclusion, we found migration to another country,
moving within country, side effects of treatment and
previous treatment to be significant risk factors for
LTFU. In order to improve follow-up for patients mov-
ing within the country it is important to increase the
communication and exchange of referral documents be-
tween health facilities. A recent meta-analysis showed
that psycho-emotional support and socio-economic sup-
port were associated with a significant improvement of
successful treatment outcomes [34]. Such support may
motivate patients to postpone their migration until after
treatment completion. Community health workers may
assist to reduce LTFU [23]. Expanding international
measures such as WHO Europe’s ‘minimum package for
cross-border TB control and care’ is crucial in order to
improve the situation of TB patients migrating to other
countries or those falling sick abroad [35]. Careful moni-
toring and management of side effects is needed and
patients who have been previously treated need extra
care to ensure treatment completion.
Endnotes
1The definitions for TB cases and treatment outcomes
used in this paper are according to the revised WHO
definitions1. However, the study population consists of
patients registered in 2011 and 2012 when the new
definitions were not yet implemented.
Abbreviations
DS TB: Drug Sensitive Tuberculosis; EPTB: Extra Pulmonary Tuberculosis;
HCW: Health Care Worker; LTFU: Loss to follow up; MDR TB: Multi-Drug-Resistant
Tuberculosis; MoH: Ministry of Health; PTB: Pulmonary Tuberculosis; ST: Successful
Treatment; TB 01 U: Multidrug-Resistant Tuberculosis patient cards; TB 01: Drug
Sensitive Tuberculosis patient cards; TB 03 U: Multidrug-Resistant Tuberculosis
register; TB 03: Drug Sensitive Tuberculosis register; TB: Tuberculosis; XDR
TB: Extensively-Drug-Resistant Tuberculosis
Acknowledgements
We are very grateful to the Ministry of Health, for giving permission for the
study, and for staff of the national TB control centre for assisting with data-
collection. We would like to thank also all medical staff from the participating
clinics for hosting the data collectors and assisting to find records and an-
swer questions on inconsistent data.
Funding
This study was funded by the United States Agency for International Development
under the USAID Tuberculosis CARE I, Cooperative Agreement No. AID-OAA-A-10-
000020.
Availability of data and materials
The datasets used and analysed during the current study is available from
the corresponding author on reasonable request.
Authors’ contributions
JW, MM, FS, SA and SV conceived the study during a protocol development
workshop. JW, FS and SA collected data. JW and SV analysed and interpreted
the data and wrote the first report. CM had a major role in rewriting the report
as a paper and doing literature search. All authors contributed to writing the
final version of the paper and read and approved the final manuscript.
Authors’ information
JW is currently working at the University of Utrecht, the Netherlands. CM is
currently working at the Royal Tropical Institute (KIT), Amsterdam, The
Netherlands. SV is currently working at the Department of Public Health,
Erasmus MC, Rotterdam, The Netherlands.
Ethics approval and consent to participate
Official permission to conduct this study was issued by the National Ethics
Committee of the Ministry of Health (MoH) Tajikistan, and all facility directors
gave permission to participate prior to data collection. No individual informed
consent was required.
Competing interests
The authors declare that they have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1KNCV Tuberculosis Foundation, Evidence team, The Hague, The Netherlands.
2Department of International Health, University Maastricht, Maastricht, The
Netherlands. 3KNCV TB Foundation, country office Tajikistan, Dushanbe,
Tajikistan. 4Republican Center for protection of population from TB,
Dushanbe, Tajikistan. 5Present address: Royal Tropical Institute (KIT),
Amsterdam, The Netherlands. 6Academic Medical Centre, AIGHD,
Wohlleben et al. BMC Infectious Diseases  (2017) 17:543 Page 7 of 8
Amsterdam, the Netherlands. 7Present address: Department of Public Health,
Erasmus MC, Rotterdam, The Netherlands.
Received: 5 November 2016 Accepted: 31 July 2017
References
1. World Health Organization. Global tuberculosis report 2013. WHO/HTM/TB/
2013.11. Geneva: WHO; 2013.
2. Caminero JA. Multidrug-resistant tuberculosis: epidemiology, risk factors and
case finding. Int J Tuberc Lung Dis. 2010;14(4):382–90.
3. do Brasil PEAA, Braga J. Meta-analysis of factors related to health services
that predict treatment default by tuberculosis patients. Cad Saúde Pública.
2008;4:485–502.
4. Isaakidis P, Casas EC, Das M, Tseretopoulou X, Ntzani EE, Ford N. Treatment
outcomes for HIV and MDR-TB co-infected adults and children: systematic
review and meta-analysis. Int J Tuberc Lung Dis. 2015;19(8):969–78.
5. Kruk ME, Schwalbe NR, Aguiar CA. Timing of default from tuberculosis
treatment: a systematic review. Tropical Med Int Health. 2008;13(5):703–12.
6. Castelnuovo B. A review of compliance to anti tuberculosis treatment and
risk factors for defaulting treatment in sub Saharan Africa. Afr Health Sci.
2010;10(4):320–4.
7. Tola HH, Tol A, Shojaeizadeh D, Garmaroudi G. Tuberculosis treatment non-
adherence and lost to follow up among TB patients with or without HIV in
developing countries: a systematic review. Iran J Public Health. 2015;44(1):1–11.
8. Johnston JC, Shahidi NC, Sadatsafavi M, Fitzgerald JM. Treatment outcomes
of multidrug-resistant tuberculosis: a systematic review and meta-analysis.
PLoS One. 2009;4(9):e6914.
9. Hasker E, Khodjikhanov M, Sayfiddinova S, Rasulova G, Yuldashova U, Uzakova G,
Butabekov I, Veen J, van der Werf MJ, Lefevre P. Why do tuberculosis patients
default in Tashkent City, Uzbekistan? A qualitative study. Int J Tuberc Lung Dis.
2010;14(9):1132–9.
10. Hasker E, Khodjikhanov M, Usarova S, Asamidinov U, Yuldashova U, van der
Werf MJ, Uzakova G, Veen J. Default from tuberculosis treatment in Tashkent,
Uzbekistan; who are these defaulters and why do they default? BMC Infect Dis.
2008;8:97.
11. Leimane V, Riekstina V, Holtz TH, Zarovska E, Skripconoka V, Thorpe LE, Laserson
K, Wells C. Clinical outcome of individualised treatment of multidrug-resistant
tuberculosis in Latvia: a retrospective cohort study. Lancet. 2005;365(9456):318–26.
12. Gelmanova IY, Keshavjee S, Golubchikova VT, Berezina VI, Strelis AK, Yanova
GV, Atwood S, Murray M. Barriers to successful tuberculosis treatment in
Tomsk, Russian Federation: non-adherence, default and the acquisition of
multidrug resistance. Bull World Health Organ. 2007;85(9):703–11.
13. Jakubowiak WM, Bogorodskaya EM, Borisov ES, Danilova DI, Kourbatova EK.
Risk factors associated with default among new pulmonary TB patients and
social support in six Russian regions. Int J Tuberc Lung Dis. 2007;11(1):46–53.
14. Jenkins HE, Ciobanu A, Plesca V, Crudu V, Galusca I, Soltan V, Cohen T. Risk
factors and timing of default from treatment for non-multidrug-resistant
tuberculosis in Moldova. Int J Tuberc Lung Dis. 2013;17(3):373–80.
15. Kliiman K, Altraja A. Predictors and mortality associated with treatment
default in pulmonary tuberculosis. Int J Tuberc Lung Dis. 2010;14(4):454–63.
16. Sanchez-Padilla E, Marquer C, Kalon S, Qayyum S, Hayrapetyan A, Varaine F,
Bastard M, Bonnet M. Reasons for defaulting from drug-resistant tuberculosis
treatment in Armenia: a quantitative and qualitative study. Int J Tuberc Lung
Dis. 2014;18(2):160–7.
17. Kuchukhidze G, Kumar AMV, de Colombani P, Khogali M, Nanava U,
Blumberg HM, Kemper RR. Risk factors associated with loss to follow-up
among multidrug-resistant tuberculosis patients in Georgia. Public Health
Action. 2014;4(Suppl 2):S41–6.
18. Tajikistan National Tuberculosis Program. Numbers of defaulters in all
oblasts and districts of Tajikistan. Dushanbe: Tajikistan National Tuberculosis
Program; 2013.
19. World Health Organization. Global tuberculosis report 2016. WHO/HTM/TB/
2016.13. Geneva: WHO; 2016.
20. Epidata. Epidata Software (DK) [Internet]. 2001 [cited 2015 Jun 03]. Available
from: http://www.epidata.dk.
21. Gilpin C, de Colombani P, Hasanova S, Sirodjiddinova U. Exploring TB-
related knowledge, attitude, behaviour, and practice among migrant
Workers in Tajikistan. Tuberc Res Treat. 2011;2011:1–10.
22. Kurbatova EV, Taylor A, Gammino VM, Bayona J, Becerra M, Danilovitz M,
Falzon D, Gelmanova I, Keshavjee S, Leimane V, Mitnick CD, Quelapio M,
Riekstina V, Vikklepp P, Zignol M, Cegielski JP. Predictors of poor outcomes
among patients treated for multidrug-resistant tuberculosis at DOTS-plus
projects. Tuberc (Edinb). 2016;92(5):397–403.
23. Toczek A, Cox H, Du Cros P, Cooke G, Ford N. Strategies for reducing
treatment default in drug-resistant tuberculosis: systematic review and
meta-analysis. Int J Tuberc Lung Dis. 2013;17(3):299–307.
24. Babalik A, Kilicaslan Z, Sevkan Caner S, Gungor G, Gonenc Ortakoylu M,
Gencer S, McCurdy SA. A registry-based cohort study of pulmonary
tuberculosis treatment outcomes in Istanbul. Turkey Jpn J Infect Dis. 2013;
66(2):115–20.
25. Borgdorff MW, Veen J, Kalisvaart NA, Broekmans JF, Nagelkerke NJD.
Defaulting from tuberculosis treatment in the Netherlands: rates, risk factors
and trend in the period 1993-1997. Eur Respir J. 2000;16(2):209–13.
26. Caylà JA, Rodrigo T, Ruiz-Manzano J, Caminero JA, Vidal R, García JM,
Blanquer R, Casals M. Tuberculosis treatment adherence and fatality in
Spain. Respir Res. 2009;10:121.
27. Cegolon L, Maguire H, Mastrangelo G, Carless J, Kruijshaar ME, Verlander NQ.
Predictors of failure to complete tuberculosis treatment in London, 2003-
2006. Int J Tuberc Lung Dis. 2010;14(11):1411–7.
28. Conwell DS, Mosher A, Khan A, Tapy J, Sandman L, Vernon A, Horsburgh
CR. Factors associated with loss to follow-up in a large tuberculosis
treatment trial (TBTC study 22). Contemp Clin Trials. 2007;28(3):288–94.
29. Diel R, Niemann S. Outcome of tuberculosis treatment in Hamburg: a
survey, 1997-2001. Int J Tuberc Lung Dis. 2003;7(2):124–31.
30. Valin N, Hejblum G, Borget I, Mallet HP, Antoun F, Che D, Chouaid C.
Management and treatment outcomes of tuberculous patients, eastern
Paris, France, 2004. Int J Tuberc Lung Dis. 2009;13(7):881–7.
31. Story A, Murad S, Roberts W, Verheyen M, Hayward AC. Tuberculosis in
London: the importance of homelessness, problem drug use and prison.
Thorax. 2007;62(8):667–71.
32. Tajikistan National Tuberculosis Program. Documentation of HIV coinfection
and other sensitive patient information. Dushanbe: Tajikistan National
Tuberculosis Program; 2014.
33. Shringarpure KS, Isaakidis P, Sagili KD, Baxi RK. Loss-to-follow-up on multidrug
resistant tuberculosis treatment in Gujarat, India: the when and who of it. PLoS
One. 2015;10(7):1–10.
34. van Hoorn R, Jaramillo E, Collins D, Gebhard A, van den Hof S. The effects of
psycho-emotional and socio-economic support for tuberculosis patients on
treatment adherence and treatment outcomes – a systematic review and
meta-analysis. PLoS One. 2016;11(4):e0154095.
35. Dara M, De Colombani P, Petrova-Benedict R, Centis R, Zellweger JP, Sandgren
A, Heldal E, Sotgiu G, Jansen N, Bahtijarevic R, Migliori GB. Minimum package
for cross-border TB control and care in the WHO European region: a Wolfheze
consensus statement. Eur Respir J. 2012;40(5):1081–90.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Wohlleben et al. BMC Infectious Diseases  (2017) 17:543 Page 8 of 8
